Human hepatocytes and uses thereof

Abstract

Disclosed herein are human hepatocytes for example isolated human hepatic progenitor cells, artificial tissue or organ thereof, and kits or compositions thereof. Also disclosed herein are various methods of using a human hepatocyte disclosed herein.

1 - 89 . (canceled) 
     
     
         90 . An isolated human hepatocyte, wherein the isolated human hepatocyte endogenously expresses transforming growth factor beta 1 (TGFβ1), fibronectin, and collagen IV. 
     
     
         91 . The isolated human hepatocyte of  claim 90 , wherein the isolated human hepatocyte is a human hepatic progenitor cell. 
     
     
         92 . The isolated human hepatocyte of  claim 90 , wherein the isolated human hepatocyte further expresses human leukocyte antigen G (HLA-G). 
     
     
         93 . The isolated human hepatocyte of  claim 90 , wherein the isolated human hepatocyte recruits CD4 + Foxp3 + Treg cells. 
     
     
         94 . The isolated human hepatocyte of  claim 90 , wherein a plurality of the isolated human hepatocytes is present in a cluster or an aggregate. 
     
     
         95 . The isolated human hepatocyte of  claim 90 , wherein a plurality of the isolated human hepatocytes forms a tissue of a 3-dimensional structure. 
     
     
         96 . The isolated human hepatocyte of  claim 90 , wherein a plurality of the isolated human hepatocytes forms a crescent cell mass. 
     
     
         97 . A kit comprising the isolated human hepatocyte of  claim 90  and a carrier. 
     
     
         98 . A pharmaceutical composition comprising the isolated human hepatocyte of  claim 90  and a pharmaceutically acceptable carrier. 
     
     
         99 . A method of treating a disorder of liver tissue or liver function in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of  claim 98 , whereby the disorder is treated. 
     
     
         100 . A method of screening a therapeutic compound for use in treatment or prevention of a condition, comprising:
 a) contacting the isolated human hepatocyte of  claim 90 , with the therapeutic compound; and   b) detecting an expression level of a biomarker in the isolated human hepatocyte.   
     
     
         101 . A method of producing a therapeutic protein, comprising culturing the isolated human hepatocyte of  claim 90  in a medium and extracting the therapeutic protein from the medium. 
     
     
         102 . A method of regenerating a liver, comprising applying the isolated human hepatocyte of  claim 90  to an ex vivo perfusion system to regenerate the liver. 
     
     
         103 . A cell therapy, comprising intravenously administering to a subject in need thereof a composition that comprises the isolated human hepatocyte of  claim 90 . 
     
     
         104 . A method of bioprinting, comprising applying the isolated human hepatocyte of  claim 90  to a bioprinting system. 
     
     
         105 . A method of generating a tissue scaffold, comprising culturing the isolated human hepatocyte of  claim 90  in a medium on a three-dimensional biocompatible substrate to generate the tissue scaffold. 
     
     
         106 . An artificial tissue or organ, comprising human hepatocytes that express alpha-1-fetoprotein (AFP), albumin (ALB), alpha-1-antitrypsin, glucose, or glycogen. 
     
     
         107 . An artificial tissue or organ, comprising human hepatocytes that endogenously express human leukocyte antigen G (HLA-G) and one or more biomarkers from C-X-C chemokine receptor type 4 (CXCR4), forkhead box protein A2 (FOXA2), hematopoietically expressed homeobox (HHEX), cytochrome P450 7A1 (CYP7A1), bile salt export pump (BSEP), alpha-1-antitrypsin member 1 (SERPINA1), ATP-binding cassette sub-family C member 2 (ABCC2), CCAAT-enhancer-binding protein beta (C/EBPβ), hepatocyte nuclear factor 1-alpha (HNF1α), or any combination thereof.